Stockreport

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress [Yahoo! Finance]

Apollomics Inc. - Class A Ordinary Shares  (APLM) 
PDF To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials. Phase 2/3 IND submission for development of vebreltini [Read more]